Plus Therapeutics/$PSTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Plus Therapeutics
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Ticker
$PSTV
Sector
Primary listing
Employees
28
Headquarters
Website
PSTV Metrics
BasicAdvanced
$46m
-
-$2.62
-
-
Price and volume
Market cap
$46m
52-week high
$8.00
52-week low
$2.90
Average daily volume
207k
Financial strength
Current ratio
2.266
Quick ratio
2.07
Total debt to equity
6.061
Profitability
EBITDA (TTM)
-18.486
Gross margin (TTM)
-61.69%
Net profit margin (TTM)
-230.24%
Operating margin (TTM)
-364.36%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-73.82%
Return on equity (TTM)
204.30%
Valuation
Price to revenue (TTM)
5.93
Price to book
3.81
Price to tangible book (TTM)
4.04
Price to free cash flow (TTM)
-1.415
Free cash flow yield (TTM)
-70.69%
Free cash flow per share (TTM)
-4.694
Growth
Revenue change (TTM)
-0.46%
Earnings per share change (TTM)
-97.68%
3-year revenue growth (CAGR)
92.19%
10-year revenue growth (CAGR)
-8.23%
3-year earnings per share growth (CAGR)
-78.55%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs